Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 02, 2021 08:00 ET | Source: Enlivex Therapeutics Ltd

Enlivex Hires Biotech Industry Veteran Tzvi Palash to Lead the Design and Construction of its New cGMP Allocetra Manufacturing Plant

Mr. Palash joins Enlivex from Gamida Cell, where he served as Chief Operating Officer, and previously served as Chief Operating Officer of Protalix Biotherapeutics, and as General Manager of ColBar...
July 21, 2021 08:00 ET | Source: Enlivex Therapeutics Ltd

Enlivex to Present at the Improvate Life-Saving Technologies International Conference 2021

Nes Ziona, Israel, July 21, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
July 14, 2021 08:00 ET | Source: Enlivex Therapeutics Ltd

Enlivex to Present at the ARDS Drug Development Summit 2021

Nes Ziona, Israel, July 14, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
July 12, 2021 08:00 ET | Source: Enlivex Therapeutics Ltd

Enlivex Initiates Design and Construction Process for a New cGMP Allocetra Manufacturing Plant

Nes Ziona, Israel, July 12, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it...
June 16, 2021 08:00 ET | Source: Enlivex Therapeutics Ltd

Enlivex Annouces Participation in A.G.P.’s Upcoming 2021 Virtual Summer Healthcare Symposium

Nes Ziona, Israel, June 16, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
June 15, 2021 08:00 ET | Source: Enlivex Therapeutics Ltd

Enlivex Announces Issuance of New European Patent Covering Therapeutic Compositions of Allocetra and CAR-T Immunotherapies for Inhibition or Reduction of Cytokine Storms Associated with CAR-T Therapies for Cancer

Nes-Ziona, Israel, June 15, 2021 (GLOBE NEWSWIRE) -- – Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
June 03, 2021 08:00 ET | Source: Enlivex Therapeutics Ltd

Enlivex to Present at the Jefferies 2021 Virtual Healthcare Conference

Nes Ziona, Israel, June 03, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
June 01, 2021 08:00 ET | Source: Enlivex Therapeutics Ltd

Enlivex Announces Issuance of New Canadian Patent Covering Pharmaceutical Compositions, Manufacturing Methods and Uses of Allocetra Immunotherapy

Nes-Ziona, Israel, June 01, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
May 18, 2021 08:00 ET | Source: Enlivex Therapeutics Ltd

Enlivex Awarded Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis

Grant provides $1.1 million in non-dilutive funding for 2021 Nes Ziona, Israel, May 18, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage...
March 22, 2021 08:00 ET | Source: Enlivex Therapeutics Ltd

Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect of Allocetra™ in Combination with Immune Checkpoint Inhibitors

Nes Ziona, Israel, March 22, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right